GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hainan Poly Pharm Co Ltd (SZSE:300630) » Definitions » 5-Year EBITDA Growth Rate

Hainan Poly Pharm Co (SZSE:300630) 5-Year EBITDA Growth Rate : 3.40% (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Hainan Poly Pharm Co 5-Year EBITDA Growth Rate?

Hainan Poly Pharm Co's EBITDA per Share for the three months ended in Sep. 2024 was ¥-0.08.

During the past 3 years, the average EBITDA Per Share Growth Rate was -16.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 3.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 25.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hainan Poly Pharm Co was 53.70% per year. The lowest was -16.90% per year. And the median was 30.90% per year.


Competitive Comparison of Hainan Poly Pharm Co's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Hainan Poly Pharm Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hainan Poly Pharm Co's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hainan Poly Pharm Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Hainan Poly Pharm Co's 5-Year EBITDA Growth Rate falls into.



Hainan Poly Pharm Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Hainan Poly Pharm Co  (SZSE:300630) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Hainan Poly Pharm Co 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Hainan Poly Pharm Co's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Hainan Poly Pharm Co Business Description

Traded in Other Exchanges
N/A
Address
No.1509 Binsheng Road, 10th Floor, Zhejiang Province, Hangzhou, CHN, 310051
Hainan Poly Pharm Co Ltd is a pharmaceutical manufacturer in China. It manufactures injections, oral solid formulations, dry suspension, and other active pharmaceutical ingredients. The products offered by the company include Azithromycin for Injection, Ganciclovir Sodium for Injection. Octreotide Acetate Injection, Trimebutine Maleate tablets, Desloratadine, Trimebutine Maleate, and GANCICLOVIR among others.
Executives
Fan De Zhu Independent director
Xie Hui Fang Supervisors
Pu Jian Executives
Xu Zhao Securities Affairs Representative
Shen Shi Hua Executives
Zhou Mao Directors, Directors, and Executives

Hainan Poly Pharm Co Headlines

No Headlines